2021 Medical Endoscope Market Analysis

According to relevant statistics, there are currently 13,000 endoscopy-related enterprises in China. In 2020, 756 new enterprises were added, a year-on-year decrease of 0.92%. In the first 10 months of 2021, 221 new enterprises were added, a year-on-year decrease of 191.40%. In October, 5 new endoscopy-related enterprises were added, a year-on-year decrease of 87.80%. In January of this year, 51 new endoscopy-related enterprises were added, a year-on-year increase of 27.50%.

Distribution of endoscopy-related enterprises (province/municipality): Guangdong has the most, followed by Shandong and Anhui.

From the provincial/municipal distribution, Guangdong ranks first with 1784 endoscopy-related enterprises, followed by Shandong Province and Anhui Province with 1171 and 1051 endoscopy-related enterprises respectively.

City distribution of endoscopy-related enterprises: Shenzhen has the most, followed by Xi'an and Hefei.

From the city distribution, Shenzhen has 927 endoscopy-related enterprises, ranking first. Xi'an and Hefei have 425 and 357 endoscopy-related enterprises respectively, ranking second and third.

In the first half of 2021, a total of 2094 hospitals were monitored to announce the endoscopy bidding results, involving 3544 endoscopy bidding data, covering 172 brands, with a total purchase quantity of 6066 and a total purchase amount of 4.373 billion yuan. Among them, the data with complete brand information disclosure totaled 2581, with a total purchase quantity of 5677 and a total purchase amount of 3.686 billion yuan, including: 2195 soft endoscopes, totaling 1.976 billion yuan; 3068 hard endoscopes, totaling 1.284 billion yuan; 296 with unclear classification, totaling 414, with a total purchase amount of 425 million yuan.

Based on the brand and amount data disclosed in the first half of the year, Olympus won 1311 bids with a total bid amount of 1.492 billion yuan, accounting for 40.5% of the market share; the top three also include Karl Storz and Fujifilm, with market shares of 15.0% and 10.6% respectively.

Top 3 in the soft endoscope market: Olympus (57.7%), Fujifilm (17.5%), Pentax (Haoya) (5.7%)

Top 3 in the hard endoscope market: Karl Storz (37.2%), Olympus (15.9%), Richard Wolf (German Wolf brand) (4.4%)

The Chinese endoscope market, by product type, includes, in addition to hard and soft endoscope bodies, corresponding equipment, parts, and endoscopy-specific therapeutic consumables. Excluding the impact of surgical consumables, the top three markets are subdivided by category into digestive endoscopy, thoracoscopy, and bronchoscopy.

In terms of competitive landscape, the Chinese endoscope market is monopolized by Japanese and German manufacturers. Due to the fact that the photosensitive component industry of traditional soft endoscopes is driven by Japanese companies, the core technology barriers are high, and Japanese companies such as Olympus, Fujifilm, and Pentax basically monopolize the soft endoscope market. Karl Storz, a German company, was the first to master the columnar endoscope technology, and German manufacturers have maintained a leading position in the hard endoscope field. Major domestic soft and hard endoscope manufacturers, such as Auhua Endoscopy, Kalamed, and Mindray Medical, cannot directly compete with imported manufacturers in the high-end market, and currently mainly target hospitals below the secondary level, and are still in the stage of rapidly catching up with imported counterparts.

Domestic manufacturers have been slow to break through and surpass in the endoscope field, and high technological barriers are the direct reason for the low domestic penetration rate. From a long-term perspective, imported manufacturers have monopolized the industry with their superior technology, and the breakthrough of domestic endoscopes is imperative. The replacement of image sensors from CCD to CMOS has brought opportunities for domestic enterprises. Currently, many enterprises have applied CMOS technology to medical endoscopes and launched many new products. Domestic enterprises have made rapid progress in CMOS technology, with a smaller gap with overseas technology, which will break away from the limitations of CCD; at the same time, years of accumulated technology will also play a unique innovative advantage of domestic enterprises, achieving overtaking on a curve. In the high-end endoscope field, domestic endoscopes have achieved technological breakthroughs, and have developed rapidly in AI and 4k.

According to statistics, the size of China's endoscope market reached 25.4 billion RMB in 2020, with a compound annual growth rate of about 14.2% from 2015 to 2020. During the same period, the global endoscope market size increased from US$16.4 billion to US$21.5 billion, with a compound annual growth rate of 5.5%. The growth rate of the Chinese market is much faster than that of the global market, and its share in the global market is constantly increasing. Currently, the main manufacturers in the domestic market are foreign companies Olympus, Fujifilm, Pentax, Karl Storz, and German Wolf brand; domestic enterprises mainly include Auhua Endoscopy, Kalamed, and Mindray Medical, etc. We will briefly introduce them below. (Some major manufacturers of hard and soft endoscopes, such as Stryker and Synergetics, are not introduced here.)

Olympus

Founded in 1919, the company not only occupies a dominant position in the soft endoscope field, but also ranks among the first echelon in the hard endoscope field, occupying 23% of the domestic market share, second only to the German company Karl Storz. In the field of endoscopes, Olympus's main endoscope products currently include digestive endoscopes, biliary endoscopes, laparoscopes, electronic gastroscopes, cystoscope, ureteroscope, percutaneous nephroscope, hysteroscope, colposcope, bronchoscope, and otolaryngoscope, etc. And recently developed a new system called EVIS LUCERA ELITE. EVIS LUCERA ELITE aims to provide higher imaging performance and easier use for physicians performing colonoscopy, with many new technologies and innovations.

Karl Storz

Since the 1940s, Karl Storz has been a globally renowned family-owned company in the research, development, and production of endoscopes and medical devices. Karl Storz's technological innovations over the past few decades have benefited almost every medical field through the transformative advancements of endoscopy and minimally invasive techniques. As a result, the range of endoscope products truly covers "head to toe", extending to veterinary medicine and industrial endoscope applications. Its new RUBINA NIR/ICG endoscope, equipped with the HOPKINS® rod lens system, not only boasts excellent image quality but also allows for precise focusing on the observed tissue and provides ample illumination of the surgical area. The matching dedicated optical system can be used with the IMAGE1 S™ 4U RUBINA camera and POWER LED RUBINA light source.

Richard Wolf German Brand

Founded in 1906 as a small family business in Berlin, it has grown into an international organization with 15 Branches and 130 distributors. It provides a variety of products and systems for endoscopy and extracorporeal shock wave therapy. The company's rigid and flexible endoscopes are mainly used in urology, orthopedics, general surgery, gynecology, otorhinolaryngology, and neurosurgery.

As an aid, the product line is also equipped with an operating room management system called core nova. The core nova system eliminates the burden of tissue management for operating room staff, making it suitable for hospitals and medical clinics. Industrial endoscopes further enhance the existing instrument product range.

Fujifilm Corporation

Established in 1934, its main businesses include imaging solutions, information solutions, and document solutions. The medical business is one of Fujifilm's core businesses. Fujifilm's endoscope product line mainly covers gastrointestinal endoscopes and systems, respiratory bronchoscopy systems, ultrasound bronchoscopy systems, and otolaryngological electronic endoscopy systems. During the China County Health Conference, Fujifilm launched the new ELUXEO Lite 6000, a cost-effective new generation endoscope system. This system is equipped with Fujifilm's exclusive LCI linked image technology and BLI blue light imaging technology, which increase the contrast of mucosal color and the recognition of surface structures, thereby significantly improving the detection rate of early cancerous lesions. It achieves accurate screening at a high cost-performance ratio, serving county-level early cancer screening work.

Auhua Endoscope

Founded in 1994, it is one of the earliest companies in China to engage in the research and manufacturing of flexible electronic endoscopes. After nearly thirty years of focus and innovation, Auhua Endoscope has broken through key endoscope technologies and has made systematic product layouts around the field of endoscope diagnosis and treatment. In 2005, Auhua Endoscope launched its first generation electronic endoscope system, the VME-2000—one of the earliest domestically produced flexible electronic endoscopes. Its emergence also broke the situation where flexible electronic endoscopes were completely dependent on imported equipment. Auhua Endoscope's AQ-200 full-HD light-transmitting endoscope system innovatively uses laser transmission technology to transmit 1080P image information. Laser transmission, in contrast to electrical signal transmission, is not susceptible to electromagnetic interference, facilitating the combined operation of high-frequency electrosurgery and other peripheral devices under the endoscope, improving the safety and convenience of clinical operations.

In general, the development of domestically produced endoscopes has been smooth, with continuous strengthening of research and development and innovation, constantly introducing new products, and catching up with foreign manufacturers in many aspects. Under China's tiered medical treatment policies and encouragement of domestic substitution, domestic brands are expected to surpass imported brands in the primary healthcare market with higher cost-effectiveness.

This information originates from the internet. Please contact us for removal if there is any infringement.

According to relevant statistics, there are currently 13,000 endoscopy-related enterprises in China. In 2020, 756 new enterprises were added, a year-on-year decrease of 0.92%. In the first 10 months of 2021, 221 new enterprises were added, a year-on-year decrease of 191.40%. In October, 5 new endoscopy-related enterprises were added, a year-on-year decrease of 87.80%. In January of this year, 51 new endoscopy-related enterprises were added, a year-on-year increase of 27.50%.

Distribution of endoscopy-related enterprises (province/municipality): Guangdong has the most, followed by Shandong and Anhui.

From the provincial/municipal distribution, Guangdong ranks first with 1784 endoscopy-related enterprises, followed by Shandong Province and Anhui Province with 1171 and 1051 endoscopy-related enterprises respectively.

City distribution of endoscopy-related enterprises: Shenzhen has the most, followed by Xi'an and Hefei.

From the city distribution, Shenzhen has 927 endoscopy-related enterprises, ranking first. Xi'an and Hefei have 425 and 357 endoscopy-related enterprises respectively, ranking second and third.

In the first half of 2021, a total of 2094 hospitals were monitored to announce the endoscopy bidding results, involving 3544 endoscopy bidding data, covering 172 brands, with a total purchase quantity of 6066 and a total purchase amount of 4.373 billion yuan. Among them, the data with complete brand information disclosure totaled 2581, with a total purchase quantity of 5677 and a total purchase amount of 3.686 billion yuan, including: 2195 soft endoscopes, totaling 1.976 billion yuan; 3068 hard endoscopes, totaling 1.284 billion yuan; 296 with unclear classification, totaling 414, with a total purchase amount of 425 million yuan.

Based on the brand and amount data disclosed in the first half of the year, Olympus won 1311 bids with a total bid amount of 1.492 billion yuan, accounting for 40.5% of the market share; the top three also include Karl Storz and Fujifilm, with market shares of 15.0% and 10.6% respectively.

Top 3 in the soft endoscope market: Olympus (57.7%), Fujifilm (17.5%), Pentax (Haoya) (5.7%)

Top 3 in the hard endoscope market: Karl Storz (37.2%), Olympus (15.9%), Richard Wolf (German Wolf brand) (4.4%)

The Chinese endoscope market, by product type, includes, in addition to hard and soft endoscope bodies, corresponding equipment, parts, and endoscopy-specific therapeutic consumables. Excluding the impact of surgical consumables, the top three markets are subdivided by category into digestive endoscopy, thoracoscopy, and bronchoscopy.

In terms of competitive landscape, the Chinese endoscope market is monopolized by Japanese and German manufacturers. Due to the fact that the photosensitive component industry of traditional soft endoscopes is driven by Japanese companies, the core technology barriers are high, and Japanese companies such as Olympus, Fujifilm, and Pentax basically monopolize the soft endoscope market. Karl Storz, a German company, was the first to master the columnar endoscope technology, and German manufacturers have maintained a leading position in the hard endoscope field. Major domestic soft and hard endoscope manufacturers, such as Auhua Endoscopy, Kalamed, and Mindray Medical, cannot directly compete with imported manufacturers in the high-end market, and currently mainly target hospitals below the secondary level, and are still in the stage of rapidly catching up with imported counterparts.

Domestic manufacturers have been slow to break through and surpass in the endoscope field, and high technological barriers are the direct reason for the low domestic penetration rate. From a long-term perspective, imported manufacturers have monopolized the industry with their superior technology, and the breakthrough of domestic endoscopes is imperative. The replacement of image sensors from CCD to CMOS has brought opportunities for domestic enterprises. Currently, many enterprises have applied CMOS technology to medical endoscopes and launched many new products. Domestic enterprises have made rapid progress in CMOS technology, with a smaller gap with overseas technology, which will break away from the limitations of CCD; at the same time, years of accumulated technology will also play a unique innovative advantage of domestic enterprises, achieving overtaking on a curve. In the high-end endoscope field, domestic endoscopes have achieved technological breakthroughs, and have developed rapidly in AI and 4k.

According to statistics, the size of China's endoscope market reached 25.4 billion RMB in 2020, with a compound annual growth rate of about 14.2% from 2015 to 2020. During the same period, the global endoscope market size increased from US$16.4 billion to US$21.5 billion, with a compound annual growth rate of 5.5%. The growth rate of the Chinese market is much faster than that of the global market, and its share in the global market is constantly increasing. Currently, the main manufacturers in the domestic market are foreign companies Olympus, Fujifilm, Pentax, Karl Storz, and German Wolf brand; domestic enterprises mainly include Auhua Endoscopy, Kalamed, and Mindray Medical, etc. We will briefly introduce them below. (Some major manufacturers of hard and soft endoscopes, such as Stryker and Synergetics, are not introduced here.)

Olympus

Founded in 1919, the company not only occupies a dominant position in the soft endoscope field, but also ranks among the first echelon in the hard endoscope field, occupying 23% of the domestic market share, second only to the German company Karl Storz. In the field of endoscopes, Olympus's main endoscope products currently include digestive endoscopes, biliary endoscopes, laparoscopes, electronic gastroscopes, cystoscope, ureteroscope, percutaneous nephroscope, hysteroscope, colposcope, bronchoscope, and otolaryngoscope, etc. And recently developed a new system called EVIS LUCERA ELITE. EVIS LUCERA ELITE aims to provide higher imaging performance and easier use for physicians performing colonoscopy, with many new technologies and innovations.

Karl Storz

Since the 1940s, Karl Storz has been a globally renowned family-owned company in the research, development, and production of endoscopes and medical devices. Karl Storz's technological innovations over the past few decades have benefited almost every medical field through the transformative advancements of endoscopy and minimally invasive techniques. As a result, the range of endoscope products truly covers "head to toe", extending to veterinary medicine and industrial endoscope applications. Its new RUBINA NIR/ICG endoscope, equipped with the HOPKINS® rod lens system, not only boasts excellent image quality but also allows for precise focusing on the observed tissue and provides ample illumination of the surgical area. The matching dedicated optical system can be used with the IMAGE1 S™ 4U RUBINA camera and POWER LED RUBINA light source.

Richard Wolf German Brand

Founded in 1906 as a small family business in Berlin, it has grown into an international organization with 15 Branches and 130 distributors. It provides a variety of products and systems for endoscopy and extracorporeal shock wave therapy. The company's rigid and flexible endoscopes are mainly used in urology, orthopedics, general surgery, gynecology, otorhinolaryngology, and neurosurgery.

As an aid, the product line is also equipped with an operating room management system called core nova. The core nova system eliminates the burden of tissue management for operating room staff, making it suitable for hospitals and medical clinics. Industrial endoscopes further enhance the existing instrument product range.

Fujifilm Corporation

Established in 1934, its main businesses include imaging solutions, information solutions, and document solutions. The medical business is one of Fujifilm's core businesses. Fujifilm's endoscope product line mainly covers gastrointestinal endoscopes and systems, respiratory bronchoscopy systems, ultrasound bronchoscopy systems, and otolaryngological electronic endoscopy systems. During the China County Health Conference, Fujifilm launched the new ELUXEO Lite 6000, a cost-effective new generation endoscope system. This system is equipped with Fujifilm's exclusive LCI linked image technology and BLI blue light imaging technology, which increase the contrast of mucosal color and the recognition of surface structures, thereby significantly improving the detection rate of early cancerous lesions. It achieves accurate screening at a high cost-performance ratio, serving county-level early cancer screening work.

Auhua Endoscope

Founded in 1994, it is one of the earliest companies in China to engage in the research and manufacturing of flexible electronic endoscopes. After nearly thirty years of focus and innovation, Auhua Endoscope has broken through key endoscope technologies and has made systematic product layouts around the field of endoscope diagnosis and treatment. In 2005, Auhua Endoscope launched its first generation electronic endoscope system, the VME-2000—one of the earliest domestically produced flexible electronic endoscopes. Its emergence also broke the situation where flexible electronic endoscopes were completely dependent on imported equipment. Auhua Endoscope's AQ-200 full-HD light-transmitting endoscope system innovatively uses laser transmission technology to transmit 1080P image information. Laser transmission, in contrast to electrical signal transmission, is not susceptible to electromagnetic interference, facilitating the combined operation of high-frequency electrosurgery and other peripheral devices under the endoscope, improving the safety and convenience of clinical operations.

In general, the development of domestically produced endoscopes has been smooth, with continuous strengthening of research and development and innovation, constantly introducing new products, and catching up with foreign manufacturers in many aspects. Under China's tiered medical treatment policies and encouragement of domestic substitution, domestic brands are expected to surpass imported brands in the primary healthcare market with higher cost-effectiveness.

This information originates from the internet. Please contact us for removal if there is any infringement.